Olanzapine-associated neuroleptic malignant syndrome

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 5, 2002, Pages 897-902

  Kontaxakis, Vassilis P ^a   Havaki Kontaxaki, Beata J ^a   Christodoulou, Nikolaos G ^a   Paplos, Konstantinos G ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Atypical antipsychotics; Neuroleptic malignant syndrome; Olanzapine

Indexed keywords

BENZODIAZEPINE; BROMOCRIPTINE; CREATINE KINASE; DANTROLENE; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LITERATURE; MALE; MEDLINE; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL DISEASE; RATING SCALE; SCHIZOPHRENIA;

BENZODIAZEPINES; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; PIRENZEPINE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 0036592332     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00202-6     Document Type: Article

References (48)

1. Addonizio G., Susman V.L., Roth S.D. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am. J. Psychiatry. 143:1986;1587-1590.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). 1994;739-742 American Psychiatric Association Publications Division, Washington, DC.
3. Apple J.E., Van Hauer G. Neuroleptic malignant syndrome associated with olanzapine therapy. letter Psychosomatics. 40:1999;267-268.
4. Beasley C.M., Tollefson G.D., Tran P.V. Safety of olanzapine. J. Clin. Psychiatry. 58(Suppl. 10):1997;13-17.
5. Burkhard P.R., Vingerhoets F.J., Alberque C., Landis T. Olanzapine-induced neuroleptic malignant syndrome. letter Arch. Gen. Psychiatry. 56:1999;101-102.
6. Caroff S.N. The neuroleptic malignant syndrome. J. Clin. Psychiatry. 41:1980;79-83.
7. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome. Med. Clin. North Am. 77:1993;185-202.
8. Caroff S.N., Mann S.C., Campbell E.C. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr. Ann. 30:2000;314-321.
9. Conley R.R., Meltzer H.Y. Adverse events related to olanzapine. J. Clin. Psychiatry. 61(Suppl. 8):2000;26-29.
10. Emborg C. Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskr. Laeg. 161:1999;1424-1425.
11. Filice G.A., McDougall B.C., Ercan-Fang N., Billington C.J. Neuroleptic malignant syndrome associated with olanzapine. Ann. Pharmacother. 32:1998;1158-1159.
12. Fulton B., Goa K.L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 53:1997;281-298.
13. Garcia Lopez M.M., Cipres L., de Cendra E., Vilalta Franch J. Neuroleptic malignant syndrome associated with olanzapine. letter Med. Clin. (Barcelona). 113:1999;239.
14. Gheorghiu S., Knobler H.Y., Drumer D. Recurrence of neuroleptic malignant syndrome with olanzapine treatment. letter Am. J. Psychiatry. 156:1999;1836.
15. 2A receptor coupled to the Jak/STAT pathway. J. Biol. Chem. 272:1997;14825-14829.
16. Gurrera R.J. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am. J. Psychiatry. 156:1999;169-180.
17. Haggarty J.M., Husni M., Peat C., Allain S. Atypical neuroleptic malignant syndrome? letter Can. J. Psychiatry. 44:1999;711-712.
18. 2A (serotonin) receptor in rat skeletal muscle. Biochem. Biophys. Res. Commun. 257:1999;369-372.
19. Hanel R.A., Sandmann M.C., Kranich M., De Bittencourt P.R. Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine. Arq. Neuro-Psiquiatr. 56:1998;833-837.
20. Hasan S., Backley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am. J. Psychiatry. 155:1998;1113-1116.
21. Hickey C., Stewart C., Lippmann S. Olanzapine and NMS. letter Psychiatr. Serv. 50:1999;836-837.
22. Jarventausta K., Leinonen E. Neuroleptic malignant syndrome during olanzapine and levopromazine treatment. Acta Psychiatr. Scand. 102:2000;231-233.
23. Johnson V., Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust. N. Z. J. Psychiatry. 32:1998;884-886.
24. Karagianis J.L., Phillips L.C., Hogan K.P., LeDrew K.K. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann. Pharmacother. 33:1999;623-630.
25. Kohen D., Bristow M. Neuroleptic malignant syndrome. Adv. Psychiatr. Treat. 2:1996;151-157.
26. Kohen D., Bristow M.F. Atypical antipsychotics and neuroleptic malignant syndrome. Br. J. Psychiatry. 175:1999;392-393.
27. Kozaric-Kovacic D., Folnegovic-Smalc V., Mimica N., Makaric G., Kocijan-Hercigonja P. Incidence of neuroleptic malignant syndrome during a 10-year follow-up at a psychiatric department. Neurol. Croat. 43:1994;87-94.
28. Levenson J.L. Neuroleptic malignant syndrome. Am. J. Psychiatry. 142:1985;1137-1145.
29. Levenson J.L. Neuroleptic malignant syndrome after the initiation of olanzapine. letter J. Clin. Psychopharmacol. 19:1999;477-478.
30. Mann S.C., Caroff S.N., Fricchione G., Campbell C.E. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr. Ann. 30:2000;363-374.
31. Marcus E.L., Vass A., Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann. Pharmacother. 6:1999;697-700.
32. Margolese H.C., Chouinard G. Olanzapine-induced neuroleptic malignant syndrome with mental retardation. letter Am. J. Psychiatry. 156:1999;1115-1116.
33. Martin J., Gomez J.C., Garcia-Bernardo E., Cuesta M., Alvarez E., Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J. Clin. Psychiatry. 58:1997;479-483.
34. Meltzer H.Y. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berlin). 150:2000;349-350.
35. Meltzer H.Y., Cola P.A., Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology. 15:1996;395-405.
36. Moltz D.A., Coeytaux R.R. Case report: possible neuroleptic malignant syndrome associated with olanzapine. letter J. Clin. Psychopharmacol. 18:1998;485-486.
37. Nopoulos P., Flaum M., Miller D.D. Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: clozapine-induced NMS without rigidity. Ann. Clin. Psychiatry. 2:1990;251-253.
38. Nyfort-Hansen K., Alderman C.P. Possible neuroleptic malignant syndrome associated with olanzapine. letter Ann. Pharmacother. 34:2000;667.
39. Prior T.I., Chue P.S., Tibbo P., Baker G.B. Drug metabolism and atypical antipsychotics. Eur. Neuropsychopharmacol. 9:1999;301-309.
40. Sachdev P., Kruk J., Kneebone M., Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J. Clin. Psychopharmacol. 15:1995;365-371.
41. Sciola A., Jeste D.V. Use of antipsychotics in the elderly. Int. J. Psychiatry Clin. Pract. 2(Suppl. 1):1998;27-34.
42. Shalev A., Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr. Scand. 73:1986;337-347.
43. Sierra-Biddle D., Herran A., Diez-Aja S., Gonzalez-Mata J.M., Vidal E., Diez-Manrique F., Vazquez-Barquero J.L. Neuroleptic malignant syndrome and olanzapine. letter J. Clin. Psychopharmacol. 20:2000;704-705.
44. Stanfield S.C., Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J. Emerg. Med. 19:2000;355-357.
45. Stephenson C.M., Pilowsky L.S. Psychopharmacology of olanzapine. A review. Br. J. Psychiatry. 174(Suppl. 38):1999;52-58.
46. Suzuki I., Honma H., Watanabe N., Matsubara S., Koyama T. A study of neuroleptic malignant syndrome in the presenium and senium. Psychiatr. Neurol. Jpn. 100:1998;387-397.
47. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M. Jr., Potvin J.H., Kiesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiatry. 58:1997;205-211.
48. Williams K., MacPherson R. Reintroduction of antipsychotics in a patient with clozapine induced neuroleptic malignant syndrome. Ir. J. Psych. Med. 14:1997;147-148.